INTRODUCTION
This analysis evaluates the effect of pharmacogenomics on key stages of the
value chain. Datamonitor assesses which therapy areas are most appropriate for
pharmacogenomics and how alliances with niche technology providers can boost the
commercial potential of the abundance of targets available in the post-genomic
era. Best practice recommendations to maximize sales of pharmacogenomics-derived
products reflect pharma's need to develop portfolios of best-in-segment or
'multi-buster' drugs.
SCOPE OF THIS REPORT
- Application of proprietary cost-effectiveness framework to assess the
therapy areas that are best suited to pharmacogenomics
- Best practice recommendations to position the benefits of pharmacogenomics-derived
drugs to patients, physicians and healthcare payers
- Evaluation of the impact of key niche genomic-based technologies on the
pharmacogenomics industry until 2012
- Analysis of the revenue opportunities associated with the 'new generation'
of blockbuster products offered by post-genomic science
- Assessment of the ability of pharmacogenomics to solve the pharmaceutical
industry's current R&D productivity crisis
REPORT HIGHLIGHTS
Micro-segmented markets do not necessarily mean reduced revenue streams for
pharmacogenomics-derived products because genotype screening identifies areas of
high unmet need. In fact, the application of pharmacogenomics in cancer
significantly increases the revenue potential of drugs with narrow therapeutic
indices.
Pharma must urgently overcome two key hurdles if they are to integrate
pharmacogenomics successfully. Firstly, post-genomic science guarantees a
10-fold increase in the number of drug targets but target validation bottlenecks
must be overcome. Secondly, traditional mass marketing is ineffective at
positioning pharmacogenomic interventions and radical new approaches are
required.
By 2010, regulatory bodies will require a diagnostic test before
pharmacogenomics-derived products are approved.
KEY REASONS TO BUY THIS REPORT
- Maximize the commercial potential of pharmacogenomics-derived products
through effective targeting of patients, physicians and payers
- Identify the clinical trial stages that benefit most from integrating
pharmacogenomics
- Target therapeutic markets effectively by applying Datamonitor's
proprietary pharmacogenomics cost-effectiveness framework
- Minimize the investment risk in accessing niche genomic-based technologies
to improve pipeline quality
- Reduce time and costs by learning from the industry's leaders when
optimizing the commercial potential of genomics-based development strategies
View Cart
